ResMed Inc (RMD)
178.81
+1.20
(+0.68%)
USD |
NYSE |
Apr 19, 16:00
178.81
0.00 (0.00%)
After-Hours: 18:17
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 26.30B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -19.48% |
| Valuation | |
| PE Ratio | 29.56 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.856 |
| Price to Book Value | 5.868 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.48 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2737 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 53.98% |
Profile
| ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting. |
| URL | https://www.resmed.com |
| Investor Relations URL | https://investors.resmed.com/investor-relations/default.aspx |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Apr. 25, 2024 |
| Last Earnings Release | Jan. 24, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 07, 2024 |
Ratings
Profile
| ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting. |
| URL | https://www.resmed.com |
| Investor Relations URL | https://investors.resmed.com/investor-relations/default.aspx |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Apr. 25, 2024 |
| Last Earnings Release | Jan. 24, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 07, 2024 |